339 related articles for article (PubMed ID: 2810823)
1. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients.
Ohuchi N; Takahashi K; Matoba N; Sato T; Taira Y; Sakai N; Masuda M; Mori S
Jpn J Clin Oncol; 1989 Sep; 19(3):242-8. PubMed ID: 2810823
[TBL] [Abstract][Full Text] [Related]
2. Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.
Filella X; Molina R; Mengual PJ; Jo J; Ballesta AM
J Nucl Biol Med (1991); 1991; 35(3):158-61. PubMed ID: 1816871
[TBL] [Abstract][Full Text] [Related]
3. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
Ohuchi N; Matoba N; Taira Y; Takahashi K; Sakai N; Sato K; Fujita N; Mochizuki F; Nishihira T; Mori S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
[TBL] [Abstract][Full Text] [Related]
4. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma.
Guadagni F; Roselli M; Amato T; Cosimelli M; Perri P; Casale V; Carlini M; Santoro E; Cavaliere R; Greiner JW
Cancer Res; 1992 Mar; 52(5):1222-7. PubMed ID: 1737383
[TBL] [Abstract][Full Text] [Related]
5. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients.
Nakayama T; Watanabe M; Teramoto T; Kitajima M
Anticancer Res; 1997; 17(2B):1379-82. PubMed ID: 9137502
[TBL] [Abstract][Full Text] [Related]
6. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
Holubec L; Topolcan O; Pikner R; Pecen L; Vaclavickova J; Wirthova M; Molacek J; Stieber P; Holdenrieder S; Sen LH; Finek J
Anticancer Res; 2000; 20(6D):5237-44. PubMed ID: 11326702
[TBL] [Abstract][Full Text] [Related]
7. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
8. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
9. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of the new tumor marker TAG-72.
Guadagni F; Roselli M; Ferroni P; Amato T; Colcher D; Greiner JW; Schlom J
Anticancer Res; 1991; 11(4):1389-94. PubMed ID: 1746895
[TBL] [Abstract][Full Text] [Related]
11. Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay.
Guadagni F; Roselli M; Cosimelli M; Spila A; Cavaliere F; Tedesco M; Arcuri R; Abbolito MR; Casale V; Pericoli MN; Vecchione A; Casciani CU; Greiner JW; Schlom J
Cancer Res; 1996 Nov; 56(22):5293-8. PubMed ID: 8912871
[TBL] [Abstract][Full Text] [Related]
12. [Significance of CA72-4 as a follow up of recurrent gastric cancer--comparison with CEA and CA19-9].
Takahashi Y; Mai M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):515-8. PubMed ID: 1558402
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer].
Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
Gebauer G; Müller-Ruchholtz W
Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011
[TBL] [Abstract][Full Text] [Related]
15. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
Gebauer G; Müller-Ruchholtz W
Anticancer Res; 1997; 17(4A):2731-4. PubMed ID: 9252706
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
[TBL] [Abstract][Full Text] [Related]
17. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
Iemura K; Moriya Y
Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
[TBL] [Abstract][Full Text] [Related]
19. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
20. [The value of tumor markers in colorectal cancer].
Peters KM; Grundmann R
Leber Magen Darm; 1989 Jan; 19(1):18-25. PubMed ID: 2927234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
